Bloom Burton Has Optimistic View of BioSyent FY2024 Earnings

BioSyent Inc. (CVE:RX) – Analysts at Bloom Burton upped their FY2024 EPS estimates for BioSyent in a research report issued to clients and investors on Thursday, November 21st. Bloom Burton analyst D. Martin now anticipates that the company will post earnings per share of $0.63 for the year, up from their prior forecast of $0.59. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2025 earnings at $0.80 EPS and FY2026 earnings at $0.91 EPS.

BioSyent Stock Performance

CVE RX opened at C$11.52 on Monday. The company has a 50-day simple moving average of C$11.06 and a two-hundred day simple moving average of C$10.29. BioSyent has a 12-month low of C$8.24 and a 12-month high of C$11.74. The firm has a market cap of C$133.52 million, a price-to-earnings ratio of 19.20 and a beta of 0.93. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19.

BioSyent (CVE:RX) last released its earnings results on Monday, August 26th. The company reported C$0.13 EPS for the quarter, meeting the consensus estimate of C$0.13. The company had revenue of C$8.95 million for the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%.

Insider Activity

In other news, Director Seyed Ahmad Ashrafi sold 2,320 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of C$10.95, for a total transaction of C$25,404.00. Also, insider FAX Capital Corp. sold 230,800 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total value of C$2,566,496.00. In the last quarter, insiders sold 234,357 shares of company stock valued at $2,605,854. Insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.